New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2013
04:55 EDTAZN, AZN, BAYRY, BAYRY, DB, DB, TEVA, TEVA, NVS, NVS, RHHBY, RHHBY, PFE, PFEFinancial Times to hold a conference
Global Pharmaceutical & Biotech Conference is being held in London, England on December 3-4.
News For AZN;BAYRY;DB;TEVA;NVS;RHHBY;PFE From The Last 14 Days
Check below for free stories on AZN;BAYRY;DB;TEVA;NVS;RHHBY;PFE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 6, 2014
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
April 4, 2014
10:45 EDTTEVAMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
April 3, 2014
14:30 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTTEVAMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
10:03 EDTRHHBYRoche unit signs companion diagnostic agreement with Genmab
Ventana Medical Systems, a member of the Roche Group, announced that it has entered into an agreement with Genmab A/S for the development of companion diagnostic tools for Genmab's HuMax-TF-ADC antibody drug conjugate program. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF-ADC.
10:00 EDTDBOn The Fly: Analyst Downgrade Summary
BB&T (BBT) downgraded to Outperform from Strong Buy at Raymond James... Broadcom (BRCM) downgraded to Neutral from Overweight at Piper Jaffray... CF Industries (CF) downgraded to Neutral from Buy at Citigroup... CSX (CSX) downgraded to Equalweight from Overweight at Barclays... Cheniere Energy (LNG) downgraded to Neutral from Outperform at Credit Suisse... Citigroup (C) downgraded to Neutral from Buy at Sterne Agee... Deutsche Bank (DB) downgraded to Neutral from Overweight at JPMorgan... G&K Services (GK) downgraded to Neutral from Outperform at RW Baird... Marcus (MCS) downgraded to Neutral from Buy at B. Riley... National Retail Properties (NNN) downgraded to Sell from Neutral at UBS... Norfolk Southern (NSC) downgraded to Neutral from Overweight at Atlantic Equities... Orion Energy (OESX) downgraded to Hold from Buy at Ascendiant... VIVUS (VVUS) downgraded to Underweight from Neutral at Piper Jaffray... Liquidity Services (LQDT) downgraded to Neutral from Outperform at RW Baird... Shaw Communications (SJR) downgraded to Sector Performer from Outperformer at CIBC... USG (USG) downgraded to Neutral from Outperform at Macquarie... Level 3 (LVLT) downgraded to Hold from Buy at Gabelli... U.S. Bancorp (USB) downgraded to Neutral from Conviction Buy at Goldman... Extra Space Storage (EXR) downgraded to Buy from Conviction Buy at Goldman... First Republic Bank (FRC) downgraded to Buy from Conviction Buy at Goldman... TELUS (TU) downgraded to Neutral from Outperform at Macquarie.
09:30 EDTPFEApple, Pfizer others create 'go slow' patent lobby group, Reuters says
Subscribe for More Information
08:27 EDTPFELeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
08:06 EDTNVSApricus Biosciences granted national phase approval for Vitaros in Luxembourg
Apricus Biosciences (APRI) announced that the Ministry of Health of Luxembourg has granted national phase approval to Vitaros, Apricus' novel topical on-demand treatment for erectile dysfunction. The company has now received a total of nine national phase approvals for Vitaros®, including Luxembourg, Belgium, France, Germany, Ireland, Italy, the Netherlands, Sweden and the United Kingdom following its broad approval by European health authorities in June 2013. Apricus has an exclusive commercialization partnership in place with Hexal AG, an affiliate within the Sandoz Division of the Novartis (NVS), for the commercialization of Vitaros in several European countries, including Luxembourg.
07:30 EDTDBMoody's left off bond deal as risk appetites grow, WSJ says
Moody's (MCO), known for adopting more-cautious stances than its rivals, was conspicuously absent from rating more than $1B in commercial-mortgage bonds that recently sold at similar yields as other recent sales, reported The Wall Street Journal. McGraw Hill Financial 's (MHFI) Standard & Poor's, Fitch and Kroll Bond Rating were called on to rate the "conduit" commercial-mortgage-backed deal organized by Deutsche Bank (DB) and Cantor Fitzgerald, the report noted. Reference Link
06:26 EDTNVSNovartis placing temporary moratorium on all IIT funding in Japan
Subscribe for More Information
06:26 EDTNVSNovartis announces third-party internal review of IITs
06:25 EDTNVSNovartis appoints Dirk Koshce as head of Novartis Pharmaceuticals
Subscribe for More Information
05:50 EDTPFEStocks with implied volatility movement; OXY PFE
Subscribe for More Information
05:38 EDTDBDeutsche Bank downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
05:31 EDTNVSNovartis says data on 19 investigational compounds to be presented
Novartis announced that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research. Among the data being presented are single agent and combination studies with key investigational compounds in the Novartis Oncology breast cancer development program, including an early phase study of the CDK4/6 inhibitor LEE011 and PI3K inhibitors BKM120 and BYL719. LEE011 and BKM120 are currently in Phase III and BYL719 is in Phase I trials for the treatment of advanced breast cancer.
April 2, 2014
11:55 EDTPFEUniqure rises after Baxter acquires Chatham Therapeutics
Subscribe for More Information
11:48 EDTTEVATeva price target raised to $66 from $57 at Standpoint Research
Subscribe for More Information
06:43 EDTDBTerra Firma appoints Goldman, Deutsche to offer Awas advice, Reuters says
Goldman Sachs (GS) and Deutsche Bank (DB) have been appointed by British private equity firm Terra Firma to offer advice on what to do with aircraft leasing firm Awas, with possible options including a possible stock market listing or complete sale, according to Reuters, citing three people familiar with the matter. Reference Link
06:34 EDTNVSNovartis price target raised to $93 from $88 at Leerink
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use